Continuous treatment strategies improve psychological status and quality of life in patients with atopic dermatitis

Table 2 Clinical symptom improvement, mean ± SD

Indicator	Intervention group (n = 60)	Control group (n = 60)	P value
Mean severity score at baseline	18.6 ± 4.2	18.4 ± 4.1	0.85
Mean severity score at 12 months	7.3 ± 2.8	11.2 ± 3.5	< 0.001
Reduction in severity score	11.3 ± 3.5	7.2 ± 3.2	< 0.001
Disease recurrence rate (%)	15.0	35.0	< 0.01
Duration of acute flares (days)	4.2 ± 1.5	7.8 ± 2.3	< 0.001
QoL	85 ± 10	75 ± 12	< 0.05
Symptom improvement rate (%)	80.0	50.0	< 0.001
Patient satisfaction score (%)	90.0	70.0	< 0.001
Frequency of acute flares (times/month)	0.5 ± 0.3	1.2 ± 0.5	< 0.001
Medication use reduction (%)	60.0	30.0	< 0.001
Sleep quality score	80 ± 10	70 ± 12	< 0.05
Physical activity level (MET-min/week)	1500 ± 300	1000 ± 200	< 0.05

QoL: Quality of life score; MET: Metabolic equivalent of task.